Oncotelic Therapeutics, Inc.
OTLC
$0.03
$0.001.00%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 250.00K | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 250.00K | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 250.00K | -- | -- | -- | -- |
| SG&A Expenses | 1.09M | 1.85M | 2.33M | 490.50K | 65.70K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.09M | 1.85M | 2.33M | 491.00K | 66.00K |
| Operating Income | -843.60K | -1.85M | -2.33M | -491.00K | -66.00K |
| Income Before Tax | 341.00K | -2.24M | 361.84M | -1.11M | 210.40K |
| Income Tax Expenses | -- | -- | 111.55M | -- | -- |
| Earnings from Continuing Operations | 341.00K | -2.24M | 250.29M | -1.11M | 210.40K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 47.10K | 45.50K | 55.00K | 67.00K | 67.40K |
| Net Income | 388.10K | -2.19M | 250.35M | -1.05M | 277.90K |
| EBIT | -843.60K | -1.85M | -2.33M | -491.00K | -66.00K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 0.00 | 0.00 | 0.57 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.57 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 447.39M | 443.80M | 441.24M | 426.44M | 408.29M |
| Average Diluted Shares Outstanding | 467.91M | 443.80M | 441.24M | 426.44M | 452.81M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |